514 related articles for article (PubMed ID: 17109645)
1. How to deal with multiple endpoints in clinical trials.
Neuhäuser M
Fundam Clin Pharmacol; 2006 Dec; 20(6):515-23. PubMed ID: 17109645
[TBL] [Abstract][Full Text] [Related]
2. Power and sample size when multiple endpoints are considered.
Senn S; Bretz F
Pharm Stat; 2007; 6(3):161-70. PubMed ID: 17674404
[TBL] [Abstract][Full Text] [Related]
3. Partition testing in dose-response studies with multiple endpoints.
Liu Y; Hsu J; Ruberg S
Pharm Stat; 2007; 6(3):181-92. PubMed ID: 17654696
[TBL] [Abstract][Full Text] [Related]
4. A note on tree gatekeeping procedures in clinical trials.
Dmitrienko A; Tamhane AC; Liu L; Wiens BL
Stat Med; 2008 Jul; 27(17):3446-51. PubMed ID: 18484599
[TBL] [Abstract][Full Text] [Related]
5. Gatekeeping procedures with clinical trial applications.
Dmitrienko A; Tamhane AC
Pharm Stat; 2007; 6(3):171-80. PubMed ID: 17583553
[TBL] [Abstract][Full Text] [Related]
6. Constructing multiple test procedures for partially ordered hypothesis sets.
Edwards D; Madsen J
Stat Med; 2007 Dec; 26(28):5116-24. PubMed ID: 17476650
[TBL] [Abstract][Full Text] [Related]
7. Evaluating co-primary endpoints collectively in clinical trials.
Li QH
Biom J; 2009 Feb; 51(1):137-45. PubMed ID: 19219905
[TBL] [Abstract][Full Text] [Related]
8. Noninferiority hypotheses and choice of noninferiority margin.
Ng TH
Stat Med; 2008 Nov; 27(26):5392-406. PubMed ID: 18680173
[TBL] [Abstract][Full Text] [Related]
9. Properties of multiple intersection-union tests for multiple endpoints in combination therapy trials.
Westfall PH; Ho SY; Prillaman BA
J Biopharm Stat; 2001; 11(3):125-38. PubMed ID: 11725927
[TBL] [Abstract][Full Text] [Related]
10. Assessment of multiple ordinal endpoints.
Häberle L; Pfahlberg A; Gefeller O
Biom J; 2009 Feb; 51(1):217-26. PubMed ID: 19197963
[TBL] [Abstract][Full Text] [Related]
11. A graphical approach to sequentially rejective multiple test procedures.
Bretz F; Maurer W; Brannath W; Posch M
Stat Med; 2009 Feb; 28(4):586-604. PubMed ID: 19051220
[TBL] [Abstract][Full Text] [Related]
12. A new partition testing strategy for multiple endpoints.
Wang B; Cui X
Stat Med; 2012 Sep; 31(20):2151-68. PubMed ID: 22532094
[TBL] [Abstract][Full Text] [Related]
13. The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases.
Lonn E
Pharmacoepidemiol Drug Saf; 2001; 10(6):497-508. PubMed ID: 11828831
[TBL] [Abstract][Full Text] [Related]
14. Some controversial multiple testing problems in regulatory applications.
Hung HM; Wang SJ
J Biopharm Stat; 2009; 19(1):1-11; discussion 12-41. PubMed ID: 19127460
[TBL] [Abstract][Full Text] [Related]
15. Bayesian design and analysis of composite endpoints in clinical trials with multiple dependent binary outcomes.
Zaslavsky BG
Pharm Stat; 2013; 12(4):207-12. PubMed ID: 23625660
[TBL] [Abstract][Full Text] [Related]
16. Multiplicity and flexibility in clinical trials.
Brannath W; Koenig F; Bauer P
Pharm Stat; 2007; 6(3):205-16. PubMed ID: 17674349
[TBL] [Abstract][Full Text] [Related]
17. An efficient method for accommodating potentially underpowered primary endpoints.
Li J; Mehrotra DV
Stat Med; 2008 Nov; 27(26):5377-91. PubMed ID: 18759248
[TBL] [Abstract][Full Text] [Related]
18. Multiple hypotheses testing based on ordered p values--a historical survey with applications to medical research.
Hommel G; Bretz F; Maurer W
J Biopharm Stat; 2011 Jul; 21(4):595-609. PubMed ID: 21516559
[TBL] [Abstract][Full Text] [Related]
19. Statistical considerations for the next generation of clinical trials.
Wu W; Shi Q; Sargent DJ
Semin Oncol; 2011 Aug; 38(4):598-604. PubMed ID: 21810519
[TBL] [Abstract][Full Text] [Related]
20. Challenges to multiple testing in clinical trials.
James Hung HM; Wang SJ
Biom J; 2010 Dec; 52(6):747-56. PubMed ID: 20589856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
